FDA first-quarter 1988 NME approvals
FDA Commissioner Young has stated publicly that "a substantial number" of approvals are likely to occur in the first three months of 1988 ("The Pink Sheet" Jan. 11, p. 10). At a Jan. 19 analysts meeting in New York, Warner-Lambert Chairman Joe Williams said that, based on a personal conversation with the commissioner, he believes the agency could approve 11 NMEs by March 31. Young has publicly committed the agency to try to spread out NDA approvals throughout the calendar year.
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.